107 related articles for article (PubMed ID: 31149728)
1. Cytochrome c1 as a favorable prognostic marker in estrogen receptor-positive breast carcinoma.
Sato A; Takagi K; Miki Y; Yoshimura A; Hara M; Ishida T; Sasano H; Suzuki T
Histol Histopathol; 2019 Dec; 34(12):1365-1375. PubMed ID: 31149728
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome c1 in ductal carcinoma in situ of breast associated with proliferation and comedo necrosis.
Chishiki M; Takagi K; Sato A; Miki Y; Yamamoto Y; Ebata A; Shibahara Y; Watanabe M; Ishida T; Sasano H; Suzuki T
Cancer Sci; 2017 Jul; 108(7):1510-1519. PubMed ID: 28394473
[TBL] [Abstract][Full Text] [Related]
3. Immunolocalization of thymidylate synthase as a favorable prognostic marker in estrogen receptor-positive breast carcinoma.
Takagi K; Miki Y; Nakamura Y; Hirakawa H; Kakugawa Y; Amano G; Watanabe M; Ishida T; Sasano H; Suzuki T
Histol Histopathol; 2015 Oct; 30(10):1223-32. PubMed ID: 25873048
[TBL] [Abstract][Full Text] [Related]
4. CYC1 Predicts Poor Prognosis in Patients with Breast Cancer.
Han Y; Sun S; Zhao M; Zhang Z; Gong S; Gao P; Liu J; Zhou J; Ma D; Gao Q; Wu P
Dis Markers; 2016; 2016():3528064. PubMed ID: 27239088
[TBL] [Abstract][Full Text] [Related]
5. Isoforms of IDH in breast carcinoma: IDH2 as a potent prognostic factor associated with proliferation in estrogen-receptor positive cases.
Minemura H; Takagi K; Sato A; Yamaguchi M; Hayashi C; Miki Y; Harada-Shoji N; Miyashita M; Sasano H; Suzuki T
Breast Cancer; 2021 Jul; 28(4):915-926. PubMed ID: 33713004
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and therapeutic relevance of phosphofructokinase platelet-type (PFKP) in breast cancer.
Umar SM; Kashyap A; Kahol S; Mathur SR; Gogia A; Deo SVS; Prasad CP
Exp Cell Res; 2020 Nov; 396(1):112282. PubMed ID: 32919954
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of WWP1 is associated with the estrogen receptor and insulin-like growth factor receptor 1 in breast carcinoma.
Chen C; Zhou Z; Sheehan CE; Slodkowska E; Sheehan CB; Boguniewicz A; Ross JS
Int J Cancer; 2009 Jun; 124(12):2829-36. PubMed ID: 19267401
[TBL] [Abstract][Full Text] [Related]
8. CITED2 in breast carcinoma as a potent prognostic predictor associated with proliferation, migration and chemoresistance.
Minemura H; Takagi K; Sato A; Takahashi H; Miki Y; Shibahara Y; Watanabe M; Ishida T; Sasano H; Suzuki T
Cancer Sci; 2016 Dec; 107(12):1898-1908. PubMed ID: 27627783
[TBL] [Abstract][Full Text] [Related]
9. D-2-hydroxyglutarate dehydrogenase in breast carcinoma as a potent prognostic marker associated with proliferation.
Hayashi C; Takagi K; Sato A; Yamaguchi M; Minemura H; Miki Y; Harada-Shoji N; Miyashita M; Sasano H; Suzuki T
Histol Histopathol; 2021 Oct; 36(10):1053-1062. PubMed ID: 34296423
[TBL] [Abstract][Full Text] [Related]
10. High IKKα expression is associated with reduced time to recurrence and cancer specific survival in oestrogen receptor (ER)-positive breast cancer.
Bennett L; Quinn J; McCall P; Mallon EA; Horgan PG; McMillan DC; Paul A; Edwards J
Int J Cancer; 2017 Apr; 140(7):1633-1644. PubMed ID: 28006839
[TBL] [Abstract][Full Text] [Related]
11. OLFM4, LY6D and S100A7 as potent markers for distant metastasis in estrogen receptor-positive breast carcinoma.
Mayama A; Takagi K; Suzuki H; Sato A; Onodera Y; Miki Y; Sakurai M; Watanabe T; Sakamoto K; Yoshida R; Ishida T; Sasano H; Suzuki T
Cancer Sci; 2018 Oct; 109(10):3350-3359. PubMed ID: 30137688
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers.
Fujimoto Y; Watanabe T; Hida AI; Higuchi T; Miyagawa Y; Ozawa H; Bun A; Fukui R; Sata A; Imamura M; Hirota S; Miyoshi Y
Breast Cancer; 2019 Nov; 26(6):738-747. PubMed ID: 31098866
[TBL] [Abstract][Full Text] [Related]
13. In situ detection of estrogen receptor dimers in breast carcinoma cells in archival materials using proximity ligation assay (PLA).
Iwabuchi E; Miki Y; Ono K; Onodera Y; Suzuki T; Hirakawa H; Ishida T; Ohuchi N; Sasano H
J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt B):159-169. PubMed ID: 27264933
[TBL] [Abstract][Full Text] [Related]
14. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
Kurozumi S; Matsumoto H; Hayashi Y; Tozuka K; Inoue K; Horiguchi J; Takeyoshi I; Oyama T; Kurosumi M
BMC Cancer; 2017 May; 17(1):354. PubMed ID: 28532429
[TBL] [Abstract][Full Text] [Related]
15. TXNIP Links Anticipatory Unfolded Protein Response to Estrogen Reprogramming Glucose Metabolism in Breast Cancer Cells.
Wang Y; Chen S
Endocrinology; 2022 Jan; 163(1):. PubMed ID: 34614512
[TBL] [Abstract][Full Text] [Related]
16. TACC2 (transforming acidic coiled-coil protein 2) in breast carcinoma as a potent prognostic predictor associated with cell proliferation.
Onodera Y; Takagi K; Miki Y; Takayama K; Shibahara Y; Watanabe M; Ishida T; Inoue S; Sasano H; Suzuki T
Cancer Med; 2016 Aug; 5(8):1973-82. PubMed ID: 27333920
[TBL] [Abstract][Full Text] [Related]
17. Expression of NgBR is highly associated with estrogen receptor alpha and survivin in breast cancer.
Wang B; Zhao B; North P; Kong A; Huang J; Miao QR
PLoS One; 2013; 8(11):e78083. PubMed ID: 24223763
[TBL] [Abstract][Full Text] [Related]
18. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous bilateral breast carcinomas: a category with frequent coexpression of HER-2 and ER-alpha, high Ki-67 and bcl-2, and low p53.
Bassarova AV; Nesland JM; Sedloev T; Lilleby W; Hristova SL; Trifonov DY; Torlakovic E
Int J Surg Pathol; 2005 Jul; 13(3):239-46. PubMed ID: 16086078
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneous Nuclear Ribonucleoprotein K Is Involved in the Estrogen-Signaling Pathway in Breast Cancer.
Iwabuchi E; Miki Y; Suzuki T; Hirakawa H; Ishida T; Sasano H
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33806648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
